Summary
Pfizer Inc.'s 2016 10-K filing highlights a dynamic year of strategic acquisitions and divestitures aimed at reshaping its business portfolio. The company completed significant acquisitions, including Medivation for approximately $14.3 billion and Anacor for $4.9 billion, bolstering its oncology and dermatology offerings, respectively. Concurrently, Pfizer divested its global infusion therapy business to ICU Medical. These moves underscore Pfizer's commitment to focusing on its Innovative Health (IH) segment, which develops novel medicines and vaccines, while the Essential Health (EH) segment continues to provide cash flow from established brands and generics. The company operates under two main segments: Innovative Health (IH) and Essential Health (EH). IH focuses on developing and commercializing innovative medicines and vaccines, with key therapeutic areas including internal medicine, oncology, inflammation & immunology, rare diseases, vaccines, and consumer healthcare. EH comprises legacy brands, branded generics, sterile injectables, and biosimilars, aiming to generate consistent cash flow. Pfizer emphasizes its robust R&D pipeline as crucial for future growth, with ongoing investments in areas like oncology, inflammation & immunology, rare diseases, and vaccines. The company also acknowledges the increasing competitive pressures from generic and biosimilar products, alongside evolving regulatory landscapes and pricing challenges globally.
Financial Highlights
56 data points| Revenue | $52.82B |
| Cost of Revenue | $12.33B |
| Gross Profit | $40.49B |
| SG&A Expenses | $14.84B |
| Operating Income | $7.20B |
| Interest Expense | $1.19B |
| Net Income | $7.21B |
| EPS (Basic) | $1.18 |
| EPS (Diluted) | $1.17 |
| Shares Outstanding (Basic) | 6.09B |
| Shares Outstanding (Diluted) | 6.16B |
Key Highlights
- 1Significant M&A activity in 2016: Acquisitions of Medivation ($14.3B) and Anacor ($4.9B) to strengthen oncology and dermatology portfolios, respectively.
- 2Divestiture of Global Infusion Therapy business (HIS) to ICU Medical for up to $900M.
- 3Reorganization of operating segments into Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) to better align with strategic focus.
- 4Strong performance in key IH products like Prevnar 13, Lyrica (ex-Europe), Enbrel (ex-US/Canada), Ibrance, Viagra (US/Canada), and Sutent.
- 5Essential Health segment continues to generate strong cash flow from established brands like Lipitor and Premarin family.
- 6Ongoing investment in R&D with a focus on key therapeutic areas including Oncology, Inflammation & Immunology, Rare Diseases, and Vaccines.
- 7Acknowledges increasing competition from generic and biosimilar products and the associated revenue risks upon patent expiries.